Collagen-based tissue engineering strategies for vascular medicine by Copes, Francesco et al.
REVIEW
published: 12 July 2019
doi: 10.3389/fbioe.2019.00166
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 1 July 2019 | Volume 7 | Article 166
Edited by:
Hasan Uludag,











This article was submitted to
Biomaterials,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 13 February 2019
Accepted: 24 June 2019
Published: 12 July 2019
Citation:
Copes F, Pien N, Van Vlierberghe S,
Boccafoschi F and Mantovani D
(2019) Collagen-Based Tissue
Engineering Strategies for Vascular
Medicine.
Front. Bioeng. Biotechnol. 7:166.
doi: 10.3389/fbioe.2019.00166
Collagen-Based Tissue Engineering
Strategies for Vascular Medicine
Francesco Copes 1,2, Nele Pien 1,3, Sandra Van Vlierberghe 3, Francesca Boccafoschi 1,2 and
Diego Mantovani 1*
1 Laboratory for Biomaterials and Bioengineering, Canada Research Chair Tier I for the Innovation in Surgery, Department of
Min-Met-Materials Engineering & Regenerative Medicine, CHU de Quebec Research Center, Laval University, Quebec City,
QC, Canada, 2 Laboratory of Human Anatomy, Department of Health Sciences, University of Piemonte Orientale, Novara,
Italy, 3 Polymer Chemistry & Biomaterials Group, Department of Organic and Macromolecular Chemistry, Centre of
Macromolecular Chemistry, Ghent University, Ghent, Belgium
Cardiovascular diseases (CVDs) account for the 31% of total death per year, making
them the first cause of death in the world. Atherosclerosis is at the root of the most
life-threatening CVDs. Vascular bypass/replacement surgery is the primary therapy for
patients with atherosclerosis. The use of polymeric grafts for this application is still
burdened by high-rate failure, mostly caused by thrombosis and neointima hyperplasia
at the implantation site. As a solution for these problems, the fast re-establishment
of a functional endothelial cell (EC) layer has been proposed, representing a strategy
of crucial importance to reduce these adverse outcomes. Implant modifications using
molecules and growth factors with the aim of speeding up the re-endothelialization
process has been proposed over the last years. Collagen, by virtue of several favorable
properties, has been widely studied for its application in vascular graft enrichment,
mainly as a coating for vascular graft luminal surface and as a drug delivery system for
the release of pro-endothelialization factors. Collagen coatings provide receptor–ligand
binding sites for ECs on the graft surface and, at the same time, act as biological sealants,
effectively reducing graft porosity. The development of collagen-based drug delivery
systems, in which small-molecule and protein-based drugs are immobilized within a
collagen scaffold in order to control their release for biomedical applications, has been
widely explored. These systems help in protecting the biological activity of the loaded
molecules while slowing their diffusion from collagen scaffolds, providing optimal effects
on the targeted vascular cells. Moreover, collagen-based vascular tissue engineering
substitutes, despite not showing yet optimal mechanical properties for their use in the
therapy, have shown a high potential as physiologically relevant models for the study
of cardiovascular therapeutic drugs and diseases. In this review, the current state of
the art about the use of collagen-based strategies, mainly as a coating material for the
functionalization of vascular graft luminal surface, as a drug delivery system for the release
of pro-endothelialization factors, and as physiologically relevant in vitro vascular models,
and the future trend in this field of research will be presented and discussed.
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INTRODUCTION AND SHORT
HISTORICAL PERSPECTIVE
Cardiovascular diseases (CVDs) account for 17.9 million deaths
each year, making them the leading cause of death in the
world (WHO1). Heart attacks and strokes account for 85%
of these deaths. Most often, atherosclerosis is at the basis
of these two pathologies. Atherosclerosis is a pathological
progressive condition in which plaques, mainly due to the
accumulation of lipids, cholesterol, foamy cells, and cellular
debris, progressively grow inside the lumens, thus leading to
the partial or complete obstruction of blood flow, and leading
to severe medical conditions and, ultimately, to death. The
increase of risk factors associated with the pathology (obesity,
diabetes, hypertension, and smoking), coupled with the increase
in average life expectancy, has led to the urgent search for
durable and effective solutions. Vascular bypass/substitution
surgery represents the most common, ultimate clinical treatment
of occlusive CVDs. Autologous blood vessels, such as saphenous
veins or radial arteries, that present the best structural,
mechanical, and biological properties are the gold standard for
this kind of application. However, the use of these substitutes
is not always possible, due to the multiple surgical procedures
required, or the poor general health conditions of patients.
Some of the limiting factors for the use of autografts include
the typical old age of the patients needing treatments, vascular
diseases preventing the use of autologous vessels, and/or previous
harvesting for other surgical treatments. In this light, the need for
other sources of vascular substitutes is critically urgent. Synthetic
prostheses development started in the 1950s and opened a
therapeutic alternative for the replacement of injured arterial
segments. The first synthetic vascular bypass has been performed
in 1952 with the implantation of a porous textile prosthesis made
of polyethylene terephthalate (PET), also known as Dacron R©
(Voorhees et al., 1952; Kannan et al., 2005). Prostheses made
of Dacron R© are usually applied for the replacement of vessels
of large caliber (>10mm in diameter). Then, in 1976, the
first use of expanded polytetrafluoroethylene (ePTFE), also
known as Teflon R©, was reported (Kannan et al., 2005; Chlupac
et al., 2009). These prostheses are applied in the replacement
of medium-sized vessels, between 6 and 10mm in diameter.
No studies show the superiority of PET compared to ePTFE
(Roll et al., 2008). Since their introduction in cardiovascular
medicine, a number of improvements have been made to
enhance the performance of the synthetic vascular substitutes
(SVS). Nevertheless, their low patency owing to short- and
intermediate-term failure still limits their clinical application.
Two of the main causes of SVS failure are thrombosis and intima
hyperplasia. In-graft thrombosis is the result of a perturbation of
the hemostatic balance, usually maintained by a series of anti-
coagulation reactions involving both physical–mechanical and
biological factors, acting on the inhibition of the coagulation
process (Edelberg et al., 2001). Among the different factors
1World Health Organization. Top 10 Causes of Death. Available online at: http://
www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/ (accessed
January 28, 2019).
acting in this complex balance, the intima layer, composed of
endothelial cells (ECs), greatly contributes to the maintenance
of the hemostatic balance by producing several antithrombotic
molecules. The disruption of the endothelial layer or its absence
greatly compromises the antithrombotic environment of healthy
blood vessels. Intimal hyperplasia, especially at the anastomotic
sites, results in the abnormal migration and proliferation of
vascular smooth muscle cells (SMCs) with associated deposition
of extracellular connective tissue matrix and is thought to be
due to a variety of injuries that always involve some endothelial
damage (Clowes, 1993). Intima hyperplasia is composed of
about 20% of vascular SMCs that have migrated from the
media to the intima and have proliferated and deposited
extracellular matrix (ECM), which comprises most (60–80%)
of the intimal area. Normal endothelium produces factors
that inhibit SMC proliferation. A damage of the endothelium
layer decreases the production of growth-inhibiting factors and
increases the expression of growth-stimulating factors, shifting
the balance toward SMC proliferation and migration toward
the intima.
As previously described, both these adverse outcomes have a
common basis in the lack or uncomplete endothelialization of
the implanted substitutes. Therefore, the rapid establishment of
a complete and functional ECs layer on the luminal surface of
SVS would be beneficial to prevent failures and for ensuring the
long-term patency of the implanted substitutes.
Tissue engineering is a multidisciplinary domain aimed to
develop biologically based tissues that can be used in the clinical
treatments of diseases. Tissue engineering products have already
shown to be effective in different applications, ranging from
burn treatment to osteo-regeneration. The success obtained by
this approach in other medical fields has opened the door
for its use in vascular reconstruction. The use of scaffolding
systems based on natural polymers is one of the strategies
used in vascular tissue engineering (vTE) to promote cellular
integration and proliferation. The ideal scaffold should be able
to mimic the native vascular ECM and the highly complex
organization of the arterial wall, showing important biological
and mechanical characteristics, such as non-thrombogenicity,
hemocompatibility, biocompatibility (low cytotoxicity, optimal
cell adhesion, bioresorbable), and non-immunogenicity, along
with tensile strength and viscoelasticity.
Among the natural polymers currently used for vTE, collagen
is the most used one. Collagen is one of the main components
of the vascular ECM. Its main function is to subdue constraints
imposed by elongation under pressure in large vessels while
providing attachment for vascular cells [12].
In this review, the main properties of the collagen molecule,
along with the different types, will be presented. Moreover,
collagen-based coatings will be detailed mainly in the context
of vascular substitutes, and the use of collagen for the
development of drug delivery systems (DDS) (with a focus
on the ones with vascular applications) will be discussed.
Finally, the development of in vitro physiologically relevant
artery models based on collagen scaffolds for the study
and validation of drugs and cardiovascular devices will be
overviewed (Figure 1).
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FIGURE 1 | Schematic view of the layout of this review.
COLLAGEN
Structure and Biosynthesis
Collagen is the most abundant protein in animals, including the
human body (Shoulders and Raines, 2009). It accounts for one
third of the total protein content, and it constitutes the main
component of the ECM. To date, 28 different collagen types have
been identified in vertebrates, and the discovery of collagen in
dinosaur bone fossils make it the oldest protein ever detected
(Exposito et al., 2002; Schweitzer et al., 2007). Collagens can
be divided into two main categories: fibrillar and non-fibrillar.
Fibrillar collagens form elongated fibril structures, which are
known for their structural role in mechanical support for most
animal tissues (Hulmes, 2002; Jenkins et al., 2005; Exposito et al.,
2010). Non-fibrillar collagens can be divided in sub-categories,
such as network-forming collagens (collagen types IV and VII),
fibril-associated collagens with interrupted triple helices (FACITs,
collagen types IX and XII), and membrane-associated collagens
with interrupted triple helices (MACITs). The main types of
collagens, along with their distribution and composition, are
listed in Table 1.
All collagens, fibrillar or not, are characterized by the same
molecular structure, which is composed of three α chains. These
chains can either be identical, thus originating a homotrimer,
or be a combination of two or three distinct α chains forming
a heterotrimer. Each α chain contains three basic amino
acids, which are glycine, proline, and hydroxyproline, and is
characterized by the presence of at least one collagenous domain,
consisting of a repeating Gly-Xaa-Yaa triplet (Brazel et al., 1987),
where Xaa is usually a proline and Yaa is a hydroxyproline.
However, both Xaa and Yaa can be any amino acid, conferring
specific functions for the collagen (Figure 2).
Fibrillar collagens are the most used in the production
of collagen-based biomaterials, with type I being the most
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TABLE 1 | Main collagen types and their distribution in the human body.
Structure Type Composition Chains Distribution
Fibrillar
Collagens
I Heterotrimer [α1(I)]2α2(I) Skin, cornea, blood
vessels, bone,
ligaments, and tendons
II Homotrimer [α1(II)]3 Cartilage, intervertebral
discs
III Homotrimer [α1(III)]3 Skin, blood vessels





XI Heterotrimer α1(XI)α2(XI)α3(XI) Cartilage, intervertebral
discs
FACITs IX Heterotrimer α1(IX)α2(IX)α3(IX) Cartilage
XII Homotrimer [α1(XII)]3 Ligaments and tendons
Network
Forming
IV Heterotrimer [α1(IV)]2α2(IV) Basal lamina




VII Homotrimer [α1(VII)]3 Under stratified
epithelium
MACITs XIII — — Endothelial cells,
dermis, eye, heart
Modified from Shoulders and Raines (2009). FACITs, fibril-associated collagens with
interrupted triple helices; MACITs, membrane-associated collagens with interrupted
triple helices.
abundant collagen type in the human body (Di Lullo et al.,
2002). During the synthesis of fibrillar collagen molecules, alpha
chains are formed by ribosomes present on the surface of rough
endoplasmic reticulum (RER). These chains present registration
peptides and a signal peptide that, once released in the lumen of
the RER, is cleaved to form pro-collagen chains (Ishikawa and
Bachinger, 2013). At this point, the pro-collagens go through
several modifications (mainly hydroxylation of the lysine and
proline residues and glycosylation of specific hydroxylysines)
and they are finally assembled in triple helical structures. These
pro-collagen triple helices are then transferred to the Golgi
apparatus to be encapsulated and secreted by exocytosis. Once in
the extracellular environment, the registration peptides present
on the pro-collagen are cleaved and tropo-collagen is formed.
Through cross-linking, several tropo-collagen molecules are
assembled to produce collagen fibrils. In turn, collagen fibrils
assemble to form collagen fibers (Bella and Hulmes, 2017).
Collagen as a Biomaterial
Collagen is the most used natural polymer for tissue engineering
applications due to its presence in the ECM of almost every
human tissue. The use of collagen as a biomaterial dates back
to the early decades of the twentieth century, when the first
characterization of the interaction between cells and extracted
collagen was studied (Huzella and Lengyel, 1932; Ehrmann
and Gey, 1956). The use of collagen is prompted by several
characteristics that make it a good material for biomedical
applications: Weak antigenicity and robust biocompatibility
(Schmitt et al., 1964; Furthmayr and Timpl, 1976; Lee et al.,
2001; Lynn et al., 2004), promotion of cell adhesion through
cell receptors that recognize a specific peptide sequence within
collagen molecules (Gullberg et al., 1992; Smethurst et al., 2007;
Konitsiotis et al., 2008), and biodegradability (Chiang et al.,
1978; Postlethwaite et al., 1978; Yannas et al., 1982). As an
added value, collagen can be isolated from several sources, being
one of the most abundant and best conserved proteins among
vertebrates. Usual sources for collagen extractions are bovine skin
and tendons (Rodrigues et al., 2003), porcine acellular bladder
collagen (Chen et al., 1999), porcine collagen type I (Salamanca
et al., 2018), and rat tail tendons (Ehrmann and Gey, 1956;
Chandrakasan et al., 1976; Habermehl et al., 2005), but collagen
has also been extracted from other organisms, such as sponges
(Exposito et al., 1991), fishes (Sugiura et al., 2009), kangaroos
(Johnson et al., 1999), and alligators (Wood et al., 2008), making
it a cost-effective solution for scaffold-based tissue engineering.
Collagen-based biomaterials are mainly used for the treatment
of burns and as wound dressing (Chattopadhyay and Raines,
2014). Due to their structure, porosity and surface properties,
collagen sponges have long been used for wound dressing
applications (Abramo and Viola, 1992; Fleck and Simman, 2010).
Moreover, they can be loaded with therapeutic agents, such as
growth factors (Lee, 2005) or antibiotics (Sripriya et al., 2004)
that greatly improve the healing process once implanted. Another
common application for collagen products is as an osteogenic
scaffold and filling material in orthopedy (Matassi et al., 2011;
Zhang et al., 2018). Collagen type I scaffolds modified with
hydroxyapatite have been used as an osteochondral scaffold to
improve bone and cartilage regeneration (Kon et al., 2011).
Collagen scaffolds can also be used as injectable mineralized
bone substitutes (Stephan et al., 2000). Next to this, collagen
has been widely used for dentistry applications, such as for the
production of membranes for periodontal and implant therapy
to improve cell proliferation (Patino et al., 2002). Another field
of application for collagen is in ophthalmology as corneal shield
(Willoughby et al., 2002; Eshar et al., 2011) and as eye implants
for post-operative recovery (Delarive et al., 2003) and corneal
implantation (Liu et al., 2006). Finally, the use of collagen as a
scaffold for the development of a DDS has attracted the attention
of many researchers all over the world (Wallace and Rosenblatt,
2003) for several applications, such as bone regeneration, eye,
cardiac, and brain medicine (Lucas et al., 1989; Kaufman et al.,
1994; Chiu et al., 2010; Chan et al., 2017) since the 1970s (Bradley
and Wilkes, 1977).
Functionalization of Collagen for Tissue
Engineering Applications
One of the most important limitations in using collagen-based
materials in regenerative medicine applications remains their
mechanical properties, which are often limited, especially at the
viscoelastic level, specifically, for vTE, mechanical properties
related to the high pressures and stresses encountered in
the blood vessel (Achilli et al., 2010; Meghezi et al., 2015).
Research has therefore focused on various ways of enhancing
and controlling the polymerization, the stability in solutions,
reducing enzymatic sensitivity, and controlling the pore
size, in an attempt to increase mechanical strength. An
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FIGURE 2 | Schematic collagen structure. (A) Collagen fiber formed by assembled collagen fibrils. (B) Collagen fibrils. (C) Assembled tropocollagen. (D) Collagen
triple helix. (E) Hydrogen bond in between collagen α chains.
FIGURE 3 | Strategies for collagen functionalization. (A) Methacrylic anhydride (Gaudet and Shreiber, 2012; Pupkaite et al., 2017); (B) 4-vinylbenzylchloride and (C)
glycidyl methacrylate (Tronci et al., 2013); (D) thiol-functionalization (Holmes et al., 2017) and (E,F) unsaturated cyclic anhydrides (Potorac et al., 2014).
interesting approach to maintain the structural integrity
of a scaffold is to chemically, physically, or enzymatically
cross-link the biopolymer (Davidenko et al., 2015; Liu et al.,
2019). However, collagen has a limited number of functional
groups (i.e., amine and carboxylic acids) that can enable
cross-linking (Gallop and Paz, 1975; Rýglová et al., 2017).
For this reason, cross-linkable modifications have been
introduced on the protein structure (Ravichandran et al., 2016)
(Figure 3). An overview of various types of modified collagen is
shown in Table 2.
COLLAGEN IN vTE
Collagen Coatings for Vascular Substitutes
One of the main complications related to the use of synthetic
vascular grafts, and especially with the ones made of PET
(Dacron), is linked to their high porosity and low elasticity.
While porosity allows tissue ingrowth, ensuring a physiological
integration of the implanted grafts, and a faster healing,
it also causes excessive bleeding, inducing potential serious
complications for the patients. Thus, the walls of the grafts must
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TABLE 2 | Overview on various functional groups that have been introduced on the collagen backbone.
Material Functional group Aim of the modification Figure References
Collagen Type I Methacrylate Sutureless wound closure A Pupkaite et al., 2017
Collagen Type I Methacrylate Mechanically heterogeneous environments A Gaudet and Shreiber, 2012
Collagen Type I 4-vinylbenzyl chloride (4VBC)
and glycidyl methacrylate (GMA)
Programmable macroscopic
properties
B, C Tronci et al., 2013




D Holmes et al., 2017
Collagen Type I + III Cyclic anhydrides Mechanical performance enhancement E, F Potorac et al., 2014
be rendered impermeable in order to avoid this outcome. For
this reason, pre-clotting is a mandatory clinical step prior to
the implantation of a Dacron (PET knitted or woven) graft.
This technique consists in the conversion of the porous wall
of the prosthesis into one that has been rendered impervious
by reaction with blood (Yates et al., 1978). Despite helping
in limiting bleeding, this technique is hampered by several
disadvantages, such as the increase of the roughness of the
luminal surface of the implanted grafts. This rougher surface
increases the occurrence of turbulent blood flow and thrombus
formation, and the increase in the rigidity of the graft
straightforwardly diminishes their pliability.
The impregnation of porous Dacron vascular grafts with
collagen was first proposed in the early 1960s (Humphries et al.,
1961) as an alternative to pre-clotting. Striking improvements
were obtained years later by Scott and colleagues in 1987
(Scott et al., 1987). Their bovine collagen-coated grafts did not
require pre-clotting or special preparation and did not bleed
once implanted in a canine model. The luminal surface of the
grafts showed neointima formation, and the collagen coating
was completely resorbed and substituted by native tissue after
3 months of implantation. Moreover, the collagen was non-
thrombogenic or antigenic. That opened the door for the use of
collagen-impregnated vascular grafts in the surgical treatment of
aneurysms and for arterial bypass (Reigel et al., 1988; Freischlag
and Moore, 1990; Noishiki et al., 1996), proving to be a viable
alternative to the previously used pre-clotting technique, being
able to compete equally against other proposed techniques and
materials (Prager et al., 2003).
Nonetheless, these collagen-coated grafts have been
demonstrated over the years not to be free from complications:
Variable inflammatory response and tissue adhesion (Jonas et al.,
1987), need of sustained chest drainage (Suehiro et al., 2003),
and initiation of the immune response (Kobayashi et al., 1993) in
the treated patients. Moreover, they showed no added value for
the replacement of small-caliber arteries (Guidoin et al., 1996).
However, the performances of the collagen-coated vascular grafts
have stood the test of time, resulting in being one of the most
used vascular grafts for medium- and large-diameter arteries
substitution nowadays.
Collagen-Based DDS
Biological signaling represents an important point in cell-driven
tissue regeneration and providing signaling molecules greatly
improves this process. However, when administering molecules
and drugs, it is of crucial importance to reach the appropriate
dose at a specific site and for the necessary period of time, in order
to accomplish the desired effects. Thus, there is a need to release
these molecules in a controlled way.
The development of collagen-based DDS for the release of
pro-angiogenetic factors for wound healing applications and pro-
endothelialization factors for vascular implant functionalization
is highly sought after. Collagen has been widely studied as a
biomaterial for DDS (Friess, 1998) and has found several uses in
a variety of applications (Table 3).
The use of collagen-based DDS for vascular applications has
been explored in recent years. Most of the studies performed
aimed to increase the affinity for the collagen scaffolds toward
ECs. The enrichment of collagen matrices with several pro-
angiogenetic growth factors, such as vascular endothelial growth
factor (VEGF) (Steffens et al., 2004; Koch et al., 2006; He et al.,
2011), stromal derived factor-1 alpha (SDF-1α) (Laiva et al.,
2018), and basic fibroblast growth factor (bFGF) (Hao et al.,
2018), has shown promising results in terms of controlling the
release of the loaded molecules and the angiogenesis induction,
which in turn results in compelling effects during wound repair
and for tissue engineering applications.
As mentioned in the Introduction, the use of synthetic
vascular grafts for the treatment of occlusive vascular diseases
is still a burden by grafts failure, mainly caused by thrombosis
and neointima hyperplasia. Implants modifications using pro-
endothelialization molecules and growth factors with the aim
of speeding up the re-endothelialization process have been
proposed over the last years to guide the optimal integration of
the grafts and to overcome the aforementioned problems. The
use of vascular graft enrichment has also been investigated. In
their work from 2000, Wissink et al. developed a heparinized,
cross-linked collagen matrix for the controlled release of bFGF to
improve the endothelialization of vascular grafts (Wissink et al.,
2000). They were able to improve the binding of the loaded
bFGF to the heparinized cross-linked matrix and to release it in
a controlled way over time, leading to an improvement in the
proliferation of treated EC in vitro.
The occurrence of infections in newly implanted synthetic
vascular grafts is one of the complications that may arise,
hampering the functionality of the prosthesis. Conventional
treatments of vascular graft infections consist in the excision
of the infected graft with extra anatomic bypass grafting
(Yeager et al., 1999). To avoid the need of another surgical
operation to treat the infected grafts, the use of DDS has
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TABLE 3 | Collagen-based drug delivery systems.
Scaffold structure Medical application Biomolecule used Cells seeded References
Growth factors/Drugs Collagen sponges Wound healing VEGF / Schroeder et al., 2007
Collagen sponges Tissue regeneration bFGF, HGF,
PDGF-BB, VEGF,
IGF-1, HB-EGF
/ Kanematsu et al., 2004
Antibacterial Gentamicin / Ivester et al., 2006
Genes Collagen gels Skin wound repair PDGF A and B
(genes)
/ Chandler et al., 2000
Cells Electrospun collagen Bone / BM-MSC Shih et al., 2006
Collagen–glycosaminoglycans
scaffold
Cardiovascular / BM-MSC Xiang et al., 2006
Collagen sponges Brain / NSC Yu et al., 2010
Collagen sponges and
hydrogels
Intervertebral discs / Human intervertebral
disc cells
Gruber et al., 2004, 2006
bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; PDGF-BB, platelet-derived growth factor-BB; IGF-1, insulin-like growth
factor-1; HB-EGF, heparin binding epidermal growth factor-like growth factor; BM-MSC, bone marrow mesenchymal stem cells; NSC, neural stem cells.
been proposed. In particular, collagen-based matrices have been
demonstrated to be effective in delivering antibiotic agents to
limit and treat bacterial infections in implanted synthetic vascular
grafts (Chervu et al., 1991; Batt et al., 2003; Schneider et al.,
2008; Herten et al., 2017), avoiding the need for subsequent
surgical interventions.
Collagen Scaffolds for Vascularization and
Artificial Blood Vessel Development
Over the years, collagen has been used as a pro-vascularization
scaffold for several applications. In fact, the ability of collagen
scaffolds to support angiogenesis and the formation of neo-
vasculature has been demonstrated (Nicosia et al., 1991).
Collagen scaffolds have been first used as an in vitro model
for the study of the angiogenetic process (Vernon et al.,
1995), but their use has been shortly translated to the clinic
(Abraham et al., 2000) for several applications. In 2008,
Shen et al. showed how a VEGF-modified collagen scaffold
was able to efficiently promote penetration, proliferation, and
assembly of ECs in the scaffold (Shen et al., 2008). In 2016,
Chan and colleagues developed a 3D scaffold from bovine
collagen type I able to support capillary formation in vivo and
vascularization once implanted in animal models (Chan et al.,
2016). Similarly, other groups demonstrated how implanted
collagen scaffolds were able to promote EC infiltration and
vascularization (Cherubino et al., 2016; Wahl et al., 2016).
Interestingly, the joint use of other ECM components along
collagen, like elastin or glycosaminoglycans, has been shown to
exert different effects on the vascularization of collagen scaffolds
(Schmidt et al., 2017).
Collagen is one of the most abundant proteins in the vascular
ECM. There, collagen fibers limit the distension of the vessel
and provide attachment for SMCs, allowing them to transmit
circumferential forces to the vessel wall, ultimately conferring
excellent mechanical support to the blood vessel wall (Bou-
Gharios et al., 2004). Therefore, the use of collagen, in particular
type I, as a scaffold in the development of tissue-engineered
vascular substitutes has been largely explored. The first use of
collagen gels to manufacture a vascular substitute dates back to
1986, when Weinberg and Bell attempted to reconstitute a blood
vessel (Weinberg and Bell, 1986). Their method consisted in the
production of a multilayered tubular construct made of collagen
seeded with SMCs and fibroblasts and of the endothelialization
of its lumen. Despite showing very low mechanical properties
and the impossibility to be used for clinical purposes, this work
marked a major advance in the field of vTE, with several groups
following in the footsteps (Hirai et al., 1994; Seliktar et al., 2000;
Boccafoschi et al., 2007) and trying to improve the system. One
of the main problems related to this kind of construct is its
mechanical properties. Different variants of the methodology
from Weinberg and Bell, such as winding leaflets around a
mandrel to promote compaction of collagen (L’Heureux et al.,
1993), magnetic pre-alignment of collagen fibers to increase
tensile strength (Tranquillo et al., 1996), cross-linking of collagen
scaffolds by glycation (Girton et al., 2000), or ultraviolet radiation
(Charulatha and Rajaram, 2003) have been developed to improve
the mechanical properties of the substitutes. However, the extent
of these improvements still does not allow the implantation
and, thus, the use in the medical practice of these grafts.
The seeded cells play an important role too: SMCs have been
demonstrated to actively influence the compaction of the collagen
scaffold (Berglund et al., 2003; Meghezi et al., 2015) and to
align along the direction of the collagen fibers (Hirai et al.,
1994), helping in increasing the mechanical properties of the
substitutes. The biological properties have also been studied.
Different molecules have been used to modulate the cellular
response toward these scaffolds. The addition of insulin and
growth factors, such as TGF-β makes it possible to increase
collagen production by the seeded cells (Long and Tranquillo,
2003), and the addition of dermatan sulfate has been able to
increase the endothelialization of the lumen and, as a result, to
reduce platelet adhesion and activation (Matsuda et al., 1988). In
recent years, hybrid collagen vascular substitutes containing both
synthetic (He et al., 2005; Stitzel et al., 2006; Jeong et al., 2007)
and natural polymers, such as fibrin (Cummings et al., 2004) and
elastin in particular (Berglund et al., 2004; Koens et al., 2010,
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2015), have been developed to further increase the mechanical
and biological properties of the collagen-based vascular grafts,
aiming to obtain an artificial vessel as close as possible to the
natural ones.
Pre-clinical and Clinical Studies of
Collagen for vTE Applications
As of today, the main use of collagen for clinical applications
is as replacement scaffolds (i.e., tissue fillers) and as support
matrices (i.e., matrix rich tissues). Collagen scaffolds used in
clinical practice primarily include skin substitutes and dermal
fillers. However, the use of collagen for other applications,
including vascular applications, is increasing. In fact, a number
of positive factors indicate that the use of a collagen-
based product is becoming an attracting prospective for
vTE purposes (Dogan et al., 2017). Table 4 shows some
of the pre-clinical studies conducted on collagen-based vTE
products. It can be observed that collagen-based materials
for vascular applications, especially for vascular grafts, are
successfully used in pre-clinical studies involving in vivo
testing and, therefore, physiological stimulation. It can be
concluded that research in the field is moving toward the






Development of 3D in vitro Models for
Cardiovascular Research
Although tissue-engineered blood vessels as living arterial
substitutes have been studied extensively in the last 25 years,
clinical translation has not yet happened (Zhang et al., 2007;
Nemeno-Guanzoni et al., 2012). The mechanism by which these
grafts integrate into the host’s circulatory system and remodel
into functional blood vessels remains unclear (Pashneh-Tala
et al., 2016). Despite this drawback, the vTE grafts can be
used as an advanced model of the vascular wall for the in
vitro testing of drugs and devices. In fact, currently used in
vitro pre-clinical models represent an overly simplified vascular
environment, not able to reproduce the complex cell–cell and
cell–environment interactions taking place in vivo. On the other
hand, in vivo animal models currently used for the development
of medical drugs and devices show limitations and disadvantages,
such as animal-to-human variations in anatomy, physiology,
and functions together with high costs and ethical burden
(Byrom et al., 2010; Swartz and Andreadis, 2013). The four
main factors to consider in order to develop a successful in
vitro vascular wall model are as follows: (i) a scaffold that
can support cell growth, (ii) an appropriate cell population,
(iii) the right biological (use of biomolecules, such as growth
factors), and (iv) mechanical stimuli to influence the proper
development of the construct (Fortunato et al., 2017). Different
research groups have been working with the final aim to develop
in vitro models able to finely mimic the wall structure of
a healthy human artery. Some examples of the development
in in vitro models, based on different approaches, can be
found in Table 5.
Collagen is widely used for the development of physiologically
relevant in vitro models (Boccafoschi et al., 2005; Seifu et al.,
2013; Pawelec et al., 2016). One of the main challenges in
developing an in vitro vascular wall model is the interaction
between the different populations of cells (Battiston et al., 2014).
Loy et al. (2016, 2018) developed an in vitro model of the
vascular wall based on collagen gels cellularized with SMCs,
fibroblasts, and ECs. In this study, the importance of co-culturing
these three vascular cell types in order to promote cell–matrix
remodeling and to obtain an early expression of elastic fiber-
related proteins was stressed. Furthermore, it was shown that the
use of a tri-culture model resulted in cell–cell interactions similar
to in vivo conditions. Another challenge in the development
of advanced in vitro vascular models, as for vTE grafts, is the
improvement of mechanical properties (i.e., compliance, burst
pressure, and elasticity) and an increase in complexity of the
model. Pezzoli et al. (2018) developed a collagen-based in vitro
model that was supplemented with human plasma fibronectin.
This resulted in an increase in elastin deposition by SMCs, as
well as an increase in the expression levels of several proteins
required for elastogenesis (i.e., fibrillin-1, lysyl oxidase, fibulin-
4, and latent TGF-β binding protein-4). The study showed how
fibronectin plays a crucial role in the production of physiological-
like, elastin-containing collagen matrices displaying superior
mechanical properties compared to the currently used models.
It has been shown that in vitro simulation of physiological
biochemical and biomechanical conditions plays a crucial role
in the development of a physiologically relevant model of the
vascular wall. To achieve this, research has focused on different
strategies, including the use of bioreactors (Bono et al., 2017;
Tresoldi et al., 2017). Bioreactors have gained large interest
because they provide the possibility to mimic a physiological
environment similar to the human in vivo situation, allowing
the improvement of both mechanical and biological properties
of in vitromodels (Arslan-Yildiz et al., 2016; Tresoldi et al., 2017;
Loy et al., 2018). The physiological-like mechanical stimulation
is of utmost importance in the development of an engineered
model of the vascular wall. The applied hemodynamic forces can
lead to improvements in the structural andmechanical properties
of the engineered construct. This is mainly due to an increased
circumferential orientation of the SMCs and the alignment of
the ECs along the flow direction, leading to a higher yield stress,
ultimate stress, and elastic modulus (Ziegler et al., 1995; Tresoldi
et al., 2017). Moreover, the simulation of physiological pulsatile
perfusion improves not only the artificial vascular development
in terms of cell alignment and organization (Houtchens et al.,
2008; Lesman et al., 2016; Asano et al., 2018), but also the
cell differentiation and phenotypic maintenance (Cevallos et al.,
2006; Li and Xu, 2007; Qiu et al., 2014), ECM production (Stanley
et al., 2000; Halka et al., 2008), vascular tone (Garoffolo et al.,
2018), and mechanical properties (Seliktar et al., 2000) of the
engineered construct (Meghezi et al., 2012; Wissing et al., 2017;
Colunga and Dalton, 2018).
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TABLE 4 | Pre-clinical and clinical studies on collagen-based vascular tissue engineering products.
Material Structure Application Implanted in References
Bovine collagen type I Porous collagen scaffolds Tissue vascularization Murine model (C57B/L6 mice) Chan et al., 2016
Rat tail type I collagen Dense gel tubes Small-diameter vascular
grafts
Murine model (Sprague–Dawley rats) Li et al., 2017




Human model (2-years-old girl with
pulmonary atresia)
Kato et al., 2016
Collagen type I and type III Porous collagen membranes Myocardial ischemia repair Rabbit model Gao et al., 2011
TABLE 5 | Vascular tissue-engineered in vitro models and strategies used.
Developed model Strategy References





Robert et al., 2013
Tubular vascular model for
inflammatory response
analysis
Collagen type I Scaffold Chen et al., 2018
Micro-vascular networks 3-D printing approach Schoneberg et al., 2018
Currently Used Collagen-Based in vitro
Models for CVDs and Drug Development
Studies
Medical drugs that contribute to blood pressure elevation or
reduction can have a great efficacy in reducing cardiovascular
risks (Cameron et al., 2016). Vasodilation and vasoconstriction
directly affect the blood vessel diameter and thus an increased
or decreased blood flow; therefore, they have an immediate
impact on the blood pressure (Toda et al., 2013). More than
80% of currently proposed pharmaceutical drug candidates that
enter clinical trials fail due to concerns with human efficacy
and toxicity (Fernandez et al., 2016). Animal responses to
drugs exhibit differences in toxic doses and drug metabolism.
Therefore, the development of in vitro models that accurately
mimic specific biological interactions, particularly relevant to
diseases, using human cells to be able to predict local responses
to administered drugs is of critical importance (Truskey and
Fernandez, 2015; Fernandez et al., 2016; Ronaldson-Bouchard
and Vunjak-Novakovic, 2018). For example, it is known that the
SMCs in the media layer of the vascular wall are fundamental
for the regulation of the vascular tone, being a key factor in the
contractile portion of the vascular wall (Wolf et al., 2016). Next
to this, the ECs layer exerts important effects on the vascular
tone too, mainly through the release of vasoconstrictor and
vasodilator molecules (Toda et al., 2013). Vaso-activity, being
the vascular activity involving the effect of either increasing or
decreasing blood pressure and/or heart rate, is considered an
important feature and a desirable characteristic for a tissue-
engineered model. It is influenced by many factors including
cell phenotype and cell–matrix interactions. Different models
have been developed over the years. The group of Laflamme
(Laflamme et al., 2005) made use of a simple SMC-based
media layer for studying the vaso-reactive properties, whereas
Fernandez et al. (2016) and Niklason et al. (1999) fabricated a
model based on a media layer combined with an EC layer to
mimic the vessel intima layer.
Fernandez et al. (2016) validated the use of non-destructive
monitoring strategies on collagen-based vascular constructs.
This strategy helped in discovering that acetylcholine, which
stimulates the release of nitric oxide, prostacyclin, and
endothelium-derived hyperpolarization factor in vessels
with a healthy and intact endothelium, is an important
vasodilator in coronary arteries, enabling the quantification
of endothelium-dependent vasodilation. On the other
hand, phenylephrine enables the non-destructive measure
of endothelium-independent vasoconstriction. The group
of Schutte has studied the functionality of collagen-based
engineered vascular media layers by looking at a large panel of
vasoactive agents that consists of drugs from both intrinsic and
extrinsic pathways (Schutte et al., 2010b). The study has shown
that the collagen-based models were capable of generating a
measurable response to several different vasoconstrictors and
vasodilators. They highlighted the importance of vaso-activity
and the functionality of developed models, as well as the
choice of a large panel of drugs to test both features. In their
work from 2016, Wolf et al. gave an overview on different
engineered vascular constructs studied for pharmacological
studies (Wolf et al., 2016). These studies demonstrate that TE
vascular constructs can be used as in vitro models to investigate
pharmacologically induced responses. However, these studies
have currently been done on simplified models of the vascular
wall using only the media and intima layer. Further research on
the evaluation of the effects of vaso-reactive stimuli on a more
advanced, complex, and physiologically relevant model of the
vascular wall is yet to be studied. It can be concluded that in vitro
models of the vascular wall show great potential and importance




and Threats of Collagen as a Biomaterial
for vTE
Despite the multiple beneficial properties and the variety of
proposed applications in vTE described in this review, the use of
collagen in vascularmedicine is still hampered by some problems.
The strength, weaknesses, opportunities, and threats (SWOT)
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FIGURE 4 | SWOT analysis for collagen as a material for vascular tissue engineering (Farndale et al., 2004; L’Heureux et al., 2006; Browne et al., 2013; Meyer, 2019).
analysis represented in Figure 4 summarizes the benefits and the
main problems and concerns related to the use of collagen in
this field.
Limits of Collagen
As mentioned in the SWOT analysis, two main limits heavily
hamper the use of collagen in vTE: collagen thrombogenicity
and its poor mechanical properties. Especially for applications
where blood contact plays a major role like in vTE, collagen
intrinsic thrombogenicity represents a major limitation. In fact,
collagen is known to be one of the major activators of platelet
response, being able to trigger and support both platelet adhesion
and activation (Farndale et al., 2004), thus impacting the
thrombogenicity of vascular devices. Thrombogenic potential,
especially for vascular graft, is a major issue, being responsible
for earlier graft occlusion (Sarkar et al., 2007). Thus, the use
of collagen has been addressed for these reasons (Guidoin
et al., 1996). Modification of the collagen through bonding
of antithrombotic agents, such as heparin has been proposed
over the years (Keuren et al., 2004; Scharn et al., 2006; Al
Meslmani et al., 2014), partially solving the issue but leaving an
open problem. Collagen plays a major role for in vivo vascular
stiffness, conferring mechanical resistance along with the other
molecules of the vascular ECM. However, extraction processes
critically compromised the mechanical strength of collagen. As
a consequence, low mechanical properties are reported as one
of the main problems related to collagen for vTE (L’Heureux
et al., 2006), thus limiting its clinical application. Over the years,
improvements have been shown through dynamic conditioning
(Seliktar et al., 2000; Buttafoco et al., 2006; Schutte et al.,
2010a) or enhanced cross-linking techniques (Brinkman et al.,
2003). Unfortunately, although these are promising techniques,
all reported cases in the literature show ultimate mechanical
properties significantly below those of native blood vessels
(Pashneh-Tala et al., 2016), once again showing the difficulties in
the clinical translation.
CONCLUSIONS AND OUTLOOK
Collagen-based scaffolds have been proven to be a versatile
biomaterial for vascular applications, gaining great achievements
in vTE. Although collagen is complex by nature, its use allowed
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 10 July 2019 | Volume 7 | Article 166
Copes et al. Collagen for Vascular Tissue Engineering
great developments in implants and drug delivery and offers
great opportunities in several fields of tissue engineering, for
dermal, cardiovascular, and connective applications. From a
scientific point of view, the open challenge remains to be able
to reproduce the hierarchically complex nature of tissues starting
from collagen. In fact, in living tissue, a number of biologically
active molecules, proteins, and cells work together in a very
dynamic environment continuously orchestrating regeneration.
From an industrial point of view, although some companies
are now able to extract, sterilize, de-immunize, neutralize, and
finally provide different types of collagen in a reproducible
manner, its cost remains prohibitive and seriously limits studies
and developments in the field. Therefore, the open challenges
remain to find alternative sources and to optimize processes
and protocols for reliable, reproducible, safe, and low-cost
collagen. Finally, accreditation and regulatory bodies are the
missed elements in this complex equation. The idea to synthesize
collagen in laboratory is an idea worthy to be further explored
and that will also facilitate the regulation concerning the collagen
structures, in the interest of the patients, and for the benefit of
the society.
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